Skip to Content
  • MyChart

    Log in to our secure, personalized website to manage your care (formerly myMDAnderson).

  • Request an Appointment

    If you are ready to make an appointment, select a button on the right. If you have questions about UT MD Anderson’s appointment process, our information page may be the best place to start.

    Appointment Information
    New Patients Current Patients Referring Physicians
  • Every Breakthrough
    Begins With You

    Gifts to UT MD Anderson’s historic philanthropic campaign help accelerate discovery, transform lives and bring hope to more patients than ever before.

    Learn more about Only Possible Here
    Donate Today only-possible-here-logo
The University of Texas MD Anderson Cancer Center
  • Clinical Trials
  • Locations
  • Careers
  • Contact Us
  • Our Doctors
    • Español
    • عربى
    • 中文
    • Türkçe
Clear
close
      MyChart
      Donate Today
      • Clinical Trials
      • Locations
      • Careers
      • Contact Us
        • Español
        • عربى
        • 中文
        • Türkçe
      • Request an Appointment
      • New Patients
      • Current Patients
      • Referring Physicians
      • Patients & Family
          • Becoming Our Patient Home
          • Why UT MD Anderson
          • Planning for Care
          • Getting to UT MD Anderson
          • While You're Here
          • International Center
          • Services and Amenities
          • Insurance & Billing
          • Second Opinion Appointments
          • Diagnosis & Treatment Home
          • Cancer Types
          • A New Diagnosis
          • Treatment Options
          • Care Centers & Clinics
          • Emotional & Physical Effects
          • Patient Support
          • Clinical Trials
          • Supporting a Loved One Home
          • Caregiver Roles & Challenges
          • Children and Teens
          • Taking Care of Yourself
          • Helping a UT MD Anderson Patient
          • Dealing with Loss
          • Life After Cancer Home
          • Follow-up Care After Cancer Treatment
          • Long-Term Effects of Cancer
          • Social & Emotional Impacts of Cancer
          • Legal & Financial Impacts of Cancer
          • Survivorship Week
        • Request an Appointment Current Patients

          Find information and resources for current and returning patients.

          Clinical Trials

          Learn about clinical trials at UT MD Anderson and search our database for open studies.

      • Prevention & Screening
          • Manage Your Risk Home
          • Tobacco Control
          • Diet
          • Body Weight
          • Physical Activity
          • Skin Safety
          • HPV
          • Hepatitis
          • Alcohol
          • Family History Home
          • Genetic Testing
          • Hereditary Cancer Syndromes
          • Genetic Counseling and Testing FAQs
          • Cancer Screenings Home
          • Mammograms & Breast Cancer Screening
          • Cervical Cancer Screening
          • Colorectal Cancer Screening
          • Endometrial Cancer Screening
          • Liver Cancer Screening
          • Lung Cancer Screening
          • Mobile Mammography
          • Ovarian Cancer Screening
          • Prostate Cancer Screening
          • Skin Cancer Screening
          • Women's Cancer Screening
          • Men's Cancer Screening
        • Cancer Prevention Center 

          The Lyda Hill Cancer Prevention Center provides cancer risk assessment, screening and diagnostic services.

      • Donors & Volunteers
          • Donate Home
          • Raise Money
          • Honor Loved Ones
          • Create Your Legacy
          • Endowments
          • Caring Fund
          • Matching Gifts
          • Foundation and Corporation Relations
          • Volunteer Home
          • Why Volunteer
          • On-Site Volunteers
          • Volunteer Endowment
          • Patient Experience
          • Teen Volunteer Leadership Program
          • Children's Cancer Hospital Councils
          • Other Ways to Help Home
          • Give Blood
          • Shop UT MD Anderson
          • Children's Art Project
          • Donate Goods or Services
          • Attend Events
          • Cord Blood Bank
          • Corporate Alliances Home
          • Current Alliances
        • Join the Campaign to End Cancer 

          Help us celebrate and fuel the groundbreaking innovations and transformative advancements that define UT MD Anderson.

      • For Physicians
          • Refer a Patient Home
          • Health Care Provider Resource Center
          • Referring Provider Team
          • Insurance Information
          • International Referrals
          • myMDAnderson for Physicians
          • Second Opinion Pathology
          • Clinical Trials Home
          • Clinical Tools & Resources Home
          • Clinical Calculators
          • Clinical Practice Algorithms
        • myMDAnderson for Physicians 

          Our personalized portal helps you refer your patients and communicate with their UT MD Anderson care team.

      • Research
          • Departments, Labs and Institutes Home
          • Departments and Divisions
          • Labs
          • Research Centers and Programs
          • Institutes
          • Specialized Programs of Research Excellence (SPORE) Grants
          • Research Areas Home
          • Basic Science
          • Translational Research
          • Clinical Research
          • Prevention & Personalized Risk Assessment
          • Research Resources Home
          • Excellence in Science
          • Core Facilities and Services
          • Conferences & Seminars
          • Why Research at UT MD Anderson
          • STRIDE
          • NCI-Designated Cancer Center
          • Data Resources
        • Clinical Trials 

          As part of our mission to eliminate cancer, UT MD Anderson researchers conduct hundreds of clinical trials to test new treatments for both common and rare cancers.

      • Education & Training
          • Degree-Granting Schools Home
          • School of Health Professions
          • MD Anderson UTHealth Houston Graduate School
          • Research Training Home
          • Early Career Pathway Programs
          • Predoctoral Training
          • Postdoctoral Training
          • Mentored Faculty Programs
          • Career Development
          • Clinical Training Home
          • Graduate Medical Education
          • Clinical Education for Non-Physicians
          • Nursing Education & Training
          • Continuing Education & Review Courses
          • Simulation Center
          • Continuing Education & Professional Development Home
          • Continuing Professional Education/Conferences
          • Administrative Internships & Fellowships
          • Cancer Survivorship Professional Education
          • Leadership Institute
          • Patient Home Visits
          • Education Resources Home
          • Alumni Relations
          • Education Design Services
          • Awards & Recognitions
          • Academic Mentoring Council
          • Why UT MD Anderson & Houston
          • Outreach Programs Home
          • Project ECHO
          • Observer Programs
          • Comparative Effectiveness Training (CERTaIN)
          • Faculty Speakers Bureau
        • Apply to SHP

          Choose from 12 allied health programs at School of Health Professions.

          Research Trainees

          View open postdoctoral and other research trainee positions.

          GME Fellowships

          Learn about our graduate medical education residency and fellowship opportunities.

      Ivo Veletic Image

      Ivo Veletic, M.D.

      Department of Leukemia - Research, Division of Cancer Medicine Division

      Present Title & Affiliation

      Primary Appointment

      Instructor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

      Education & Training

      Degree-Granting Education

      2014University of Zagreb School of Medicine, Zagreb, HR, Medicine, Doctor of Medicine (M.D.)

      Postgraduate Training

      2026-2026Postgraduate Course in Clinical Pharmacology, Drug Development & Regulation, Tufts Center for the Study of Drug Development, Tufts University School of Medicine, Boston, MA
      2025-2025Executive Healthcare Leadership Certificate Program, eCornell, Cornell University, Ithaca, NY
      2022-2023LEADing Others Core Curriculum Course, Leadership Institute, The University of Texas MD Anderson Cancer Center, Houston, Texas
      2015-2020Postdoctoral Fellowship, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
      2014-2015Internship Program for Medical Doctors in Croatia, Croatian Health Insurance Fund, Zagreb

      Licenses & Certifications

      2015Croatia Medical Licensing Certification

      Honors & Awards

      2021Rolanette and Berdon Lawrence Research Award, Baylor College of Medicine / MD Anderson / UTHealth Bone Disease Program of Texas
      2013Special Dean’s Award, University of Zagreb School of Medicine, Croatia
      2010Special Rector’s Award, University of Zagreb, Croatia
      2007National Scholarship, Ministry of Science and Education, Croatia

      Professional Memberships

      European Hematology Association

      2018 - 2020

      American Society of Hematology

      2016 - 2018

      National Postdoctoral Association

      2015 - 2020

      Selected Presentations & Talks

      Local Presentations

      1. 2026. Role of Fibrocytes and Mesenchymal Stromal Cells in Myelofibrosis. Invited. Hematopoietic Biology & Malignancy Seminar Series. Houston, Texas, US.
      2. 2024. Spatiotemporal Mapping of Bone Marrow Dynamics in Myelofibrosis and Acute Myeloid Leukemia. Invited. Spatial Biology: Multiplex Multi-Omics Seminar. Houston, TX, US.
      3. 2023. Mechanisms of Bone Marrow Fibrosis in Myelofibrosis. Invited. Zeev Estrov Leukemia Research Meeting. Houston, TX, US.
      4. 2023. Neoplastic Fibrocytes: A Target for Therapy in Myelofibrosis. Invited. Emil J Freireich Hematology Grand Rounds. Houston, TX, US.
      5. 2023. Targeting neoplastic fibrocytes in myelofibrosis. Invited. Zeev Estrov Leukemia Research Meeting. Houston, TX, US.
      6. 2022. Central role of neoplastic monocyte-derived cells in the pathogenesis of myelofibrosis. Invited. Hematopathology WHO on Hematopoietic/Lymphoid Tissues. Houston, TX, US.
      7. 2021. Role of neoplastic monocytes and T cells in the pathogenesis of PMF. Invited. Zeev Estrov Leukemia Research Meeting. Houston, TX, US.
      8. 2019. Update on classic myeloproliferative neoplasms: Fibrotic transformation. Invited. Zeev Estrov Leukemia Research Meeting. Houston, TX, US.
      9. 2019. Bone marrow beyond the complexity: Using high-dimensional imaging to understand myelofibrosis. Invited. CyTOF Mass Cytometry Annual User Group Meeting. Houston, TX, US.

      Regional Presentations

      1. 2021. Role of the JAK-STAT pathway in the induction of osteosclerosis in myelofibrosis. Conference. Bone Disease Program of Texas Annual Retreat. Houston, TX, US.

      International Presentations

      1. 2025. Quantitative profiling and clinical correlative analysis of fibrocytes and mesenchymal stromal cells in myelofibrosis spleen. Poster. 67th ASH Annual Meeting and Exposition. Orladno, US.
      2. 2025. The Pathogenetic Role of LIF in CLL. Invited. CLL Global Alliance Annual Meeting 2025. Houston, US.
      3. 2024. Temporal Dynamics of Bone Marrow Fibrocytes in the Progression of Primary Myelofibrosis. Poster. 66th ASH Annual Meeting and Exposition. San Diego, US.
      4. 2024. The Oncogenic Properties of CLL Cell-Derived Exosomes. Invited. CLL Global Alliance Annual Meeting 2024. Houston, US.
      5. 2023. Neoplastic Monocyte-Derived Fibrocytes Induce Bone Marrow Fibrosis in Patients with Primary Myelofibrosis. Poster. 65th ASH Annual Meeting and Exposition. San Diego, US.
      6. 2023. CLL Cell-Derived Exosomes Impair Immune Function and Normal Hematopoiesis in CLL. Poster. 65th ASH Annual Meeting and Exposition. San Diego, US.
      7. 2023. CLL cell-derived exosomes impair immune function and normal hematopoiesis in CLL. Invited. CLL Global Alliance Annual Meeting 2023. Houston, US.
      8. 2022. STAT3 Induces the Expression of PTX3 in CLL cells. Invited. CLL Global Alliance Annual Meeting 2022. Houston, US.
      9. 2021. GLI1 promotes the pro-fibrotic function of monocyte-derived fibrocytes in myelofibrosis. Poster. SOHO 2021 Annual Meeting. Houston, US.
      10. 2017. Neoplastic Monocyte-Derived Osteoclasts Are Highly Proliferative, but Sub-Functional in MPN-Associated Myelofibrosis. Poster. 59th ASH Annual Meeting and Exposition. Atlanta, US.
      11. 2016. Multiplex Quantitative Imaging Analysis of Bone-Remodeling Cells in Patients with Myelofibrosis. Poster. 58th ASH Annual Meeting and Exposition. San Diego, US.
      Read More
      Less

      Grant & Contract Support

      Date: 2024 - 2027
      Title:Investigating the Impact of Interferon Gamma Signaling on Therapeutic Resistance in Acute Myeloid Leukemia
      Funding Source:Cancer Prevention and Research Institute of Texas
      Role:Co-I
      ID:RP240287 (FP00019852)
      Date: 2022 - 2024
      Title:Nanoparticle-Mediated Targeting of Monocytes in Primary Myelofibrosis
      Funding Source:Avilect Biosciences, Inc. / Aviceda Therapeutics, Inc
      Role:PI
      ID:LS2022-00060725
      Date: 2021 - 2022
      Title:Role of the JAK-STAT Pathway in the Induction of Osteosclerosis in Myelofibrosis
      Funding Source:Baylor College of Medicine / MD Anderson Cancer Center / UTHealth Bone Disease Program of Texas
      Role:PI
      ID:FP00015007

      Selected Publications

      Peer-Reviewed Articles

      1. Dasdemir E, Veletic I, Ly CP, Quesada AE, Pacheco CD, Jelloul FZ, Borges P, Basu S, Jindal S, Wang Z, Lazar A, Wani KM, Antunes DA, Reville PK, Gunaratne PH, Tower RJ, Sharma P, Abbas HA. Integrative spatial multi-omics reveal niche-specific inflammatory signaling and differentiation hierarchies in AML. iScience, 2026. e-Pub 2026. PMID: 41536977.
      2. Ferri-Borgogno S, Stolley DL, Gamal BT, Pacheco CD, Veletic I, Basi A, Mak DH, McAllister MK, Lin AJ, Gomez JA, Casasent AK, Burks JK. Dual-modality Molecular Cartography: Integrating Multiplex mRNA Detection with Protein Imaging Mass Cytometry. J Vis Exp, 2025. e-Pub 2025. PMID: 41325369.
      3. Reville PK, Wang B, Marvin-Peek J, Yuan B, Kuo YA, Garza AI, Root JL, Qiao W, Arruda A, Veletic I, Liu Y, Short NJ, DiNardo CD, Kadia TM, Daver NG, Lorenzi PL, Sasaki K, Kornblau SM, Minden MD, Ravandi F, Kantarjian HM, Abbas HA. Blood-based proteomic profiling identifies OSMR as a novel biomarker of AML outcomes. Blood 145(25):3015-3029, 2025. e-Pub 2025. PMID: 40179376.
      4. Veletic I, Harris DM, Rozovski U, Bertilaccio MTS, Calin G, Takahashi K, Li P, Liu Z, Manshouri T, Drula RC, Furudate K, Muftuoglu M, Hossain A, Wierda WG, Keating MJ, Estrov Z. CLL cell-derived exosomes alter the immune and hematopoietic systems. Leukemia 39(6):1380-1394, 2025. e-Pub 2025. PMID: 40186065.
      5. Ly CP, Veletic I, Pacheco CD, Dasdemir E, Jelloul FZ, Ferri-Borgogno S, Basi AV, Gomez JA, Root JL, Reville PK, Jindal S, Basu S, Sharma P, Quesada AE, Bueso-Ramos C, Manshouri T, Cuglievan B, Garcia M, Burks JK, Abbas HA. Multimodal spatial proteomic profiling in acute myeloid leukemia. NPJ Precis Oncol 9(1):148, 2025. e-Pub 2025. PMID: 40394148.
      6. Wang B, Reville PK, Yassouf MY, Jelloul FZ, Ly C, Desai PN, Wang Z, Borges P, Veletic I, Dasdemir E, Burks JK, Tang G, Guo S, Garza AI, Nasnas C, Vaughn NR, Baran N, Deng Q, Matthews J, Gunaratne PH, Antunes DA, Ekmekcioglu S, Sasaki K, Garcia M, Cuglievan B, Hao D, Daver N, Green MR, Konopleva M, Futreal A, Post SM, Abbas HA. Comprehensive characterization of IFNγ signaling in acute myeloid leukemia reveals prognostic and therapeutic strategies. Nat Commun 15(1):1821, 2024. e-Pub 2024. PMID: 38418901.
      7. Verstovsek S, Foltz L, Gupta V, Hasserjian R, Manshouri T, Mascarenhas J, Mesa R, Pozdnyakova O, Ritchie E, Veletic I, Gamel K, Hamidi H, Han L, Higgins B, Trunzer K, Uguen M, Wang D, El-Galaly TC, Todorov B, Gotlib J. Safety and efficacy of zinpentraxin alfa as monotherapy or in combination with ruxolitinib in myelofibrosis: stage I of a phase II trial. Haematologica 108(10):2730-2742, 2023. e-Pub 2023. PMID: 37165840.
      8. Rozovski U, Veletic I, Harris DM, Li P, Liu Z, Jain P, Manshouri T, Ferrajoli A, Burger JA, Bose P, Thompson PA, Jain N, Wierda WG, Verstovsek S, Keating MJ, Estrov Z. STAT3 Activates the Pentraxin 3 Gene in Chronic Lymphocytic Leukemia Cells. J Immunol 208(12):2847-2855, 2022. e-Pub 2022. PMID: 35595309.
      9. Manshouri T, Veletic I, Li P, Yin CC, Post SM, Verstovsek S, Estrov Z. GLI1 activates pro-fibrotic pathways in myelofibrosis fibrocytes. Cell Death Dis 13(5):481, 2022. e-Pub 2022. PMID: 35595725.
      10. Veletic I, Prijic S, Manshouri T, Nogueras-Gonzalez GM, Verstovsek S, Estrov Z. Altered T-cell subset repertoire affects treatment outcome of patients with myelofibrosis. Haematologica 106(9):2384-2396, 2021. e-Pub 2021. PMID: 32732359.
      11. Rozovski U, Harris DM, Li P, Liu Z, Jain P, Manshouri T, Veletic I, Ferrajoli A, Bose P, Thompson P, Jain N, Verstovsek S, Wierda W, Keating MJ, Estrov Z. STAT3 induces the expression of GLI1 in chronic lymphocytic leukemia cells. Oncotarget 12(5):401-411, 2021. e-Pub 2021. PMID: 33747356.
      12. Manshouri T, Verstovsek S, Harris DM, Veletic I, Zhang X, Post SM, Bueso-Ramos CE, Estrov Z. Primary myelofibrosis marrow-derived CD14+/CD34- monocytes induce myelofibrosis-like phenotype in immunodeficient mice and give rise to megakaryocytes. PLoS One 14(9):e0222912, 2019. e-Pub 2019. PMID: 31569199.
      13. Veletic I, Manshouri T, Multani AS, Yin CC, Chen L, Verstovsek S, Estrov Z. Myelofibrosis osteoclasts are clonal and functionally impaired. Blood 133(21):2320-2324, 2019. e-Pub 2019. PMID: 30745304.
      14. Lucijanic M, Veletic I, Rahelic D, Pejsa V, Cicic D, Skelin M, Livun A, Tupek KM, Stoos-Veic T, Lucijanic T, Maglicic A, Kusec R. Assessing serum albumin concentration, lymphocyte count and prognostic nutritional index might improve prognostication in patients with myelofibrosis. Wien Klin Wochenschr 130(3-4):126-133, 2018. e-Pub 2018. PMID: 29372410.
      15. Rozovski U, Harris DM, Li P, Liu Z, Jain P, Veletic I, Ferrajoli A, Burger J, Thompson P, Jain N, Wierda W, Keating MJ, Estrov Z. Activation of the B-cell receptor successively activates NF-κB and STAT3 in chronic lymphocytic leukemia cells. Int J Cancer 141(10):2076-2081, 2017. e-Pub 2017. PMID: 28722170.
      16. Rozovski U, Harris DM, Li P, Liu Z, Jain P, Veletic I, Ferrajoli A, Burger J, O'Brien S, Bose P, Thompson P, Jain N, Wierda W, Keating MJ, Estrov Z. Constitutive Phosphorylation of STAT3 by the CK2-BLNK-CD5 Complex. Mol Cancer Res 15(5):610-618, 2017. e-Pub 2017. PMID: 28130399.
      17. Jain P, Keating M, Renner S, Cleeland C, Xuelin H, Gonzalez GN, Harris D, Li P, Liu Z, Veletic I, Rozovski U, Jain N, Thompson P, Bose P, DiNardo C, Ferrajoli A, O'Brien S, Burger J, Wierda W, Verstovsek S, Kantarjian H, Estrov Z. Ruxolitinib for symptom control in patients with chronic lymphocytic leukaemia: a single-group, phase 2 trial. Lancet Haematol 4(2):e67-e74, 2017. e-Pub 2017. PMID: 28089238.

      Abstracts

      1. Baran N, Lodi A, Patel S, Ortiz JE, Collins M, Sharma P, Mohanty V, Dede M, Veletic I, Ramage CL, Park JH, Dhungana Y, Skwarska A, Zhou Y, Zeng Z, Weng C, Hayes K, Alatrash G, Dunner K, Marszalek JR, Borthakur G, Yu J, Thandapani P, Davis R, Kaipparettu BA, Chen K, Bhattacharya PK, Tiziani S, Konopleva M. CRISPR-Cas9 screen-driven identification of metabolic vulnerabilities reveals synthetic lethality via synergistic targeting of mitochondrial energy pathways and lactate export in oxphosdependent T-ALL. 67th ASH Annual Meeting and Exposition, 2025. e-Pub 2025.
      2. Muftuoglu M, Muftuoglu M, Singh S, Singh S, Bedoy A, Bedoy A, Li L, Li L, Basyal M, Basyal M, Dipmoy N, Dipmoy N, Ostermann L, Ostermann L, Veletic I, Veletic I, Pacheco C, Pacheco C, Mak PY, Mak PY, Ayoub E, Ayoub E, Kim T, Kim T, Garland K, Garland K, Pierce R, Pierce R, Angel M, Angel M, Luther S, Luther S, Rohde C, Rohde C, Andreeff M, Andreeff M. Gene-modified iPSC-derived MSCs convert immunosuppressive tumor microenvironments (TMEs) into distinct Pro-inflammatory tmes. 67th ASH Annual Meeting and Exposition, 2025. e-Pub 2025.
      3. Veletic I, Manshouri T, Pacheco C, Ly C, Yin CC, Burks J, Pemmaraju N, Masarova L, Bose P, Abbas H, Dunbar A. Quantitative profiling and clinical correlative analysis of fibrocytes and mesenchymal stromal cells in myelofibrosis spleen. 67th ASH Annual Meeting and Exposition, 2025. e-Pub 2025.
      4. Okeleji O, Singh S, Bedoy A, Ostermann L, Garland KM, Mak PY, Pacheco C, Ayoub E, Veletic I, Angel M, Luther S, Rohde C, Andreeff M. iPSC-derived mesenchymal stromal cells (iMSC) provide superior support for hematopoietic reconstitution compared to BM-MSCs. 67th ASH Annual Meeting and Exposition, 2025. e-Pub 2025.
      5. Singh S, Bedoy A, Muftuoglu M, Li L, Okeleji O, Dipmoy N, Ostermann L, Veletic I, Pacheco C, Basyal M, Kim T, Garland KM, Angel M, Luther S, Rohde C, Andreeff M, Anand V. Engineered IL7/IL15 secreting iPSC-derived mesenchymal stromal cells reprogram the immunosuppressive tumor microenvironment and potentiate antitumor immunity. 67th ASH Annual Meeting and Exposition, 2025. e-Pub 2025.
      6. Nguyen AH, Xiao W, Veletic I, Manshouri T, Braish J, El Hajjar G, Issa G, Pemmaraju N, Masarova L, Bose P, Abbas H. Clinical, molecular, and demographic features of systemic mastocytosis: Analysis of a large cohort. 67th ASH Annual Meeting and Exposition, 2025. e-Pub 2025.
      7. Xiao W, Nguyen AH, Veletic I, Manshouri T, Pemmaraju N, Masarova L, Bose P, Abbas H. Integrative proteomics and machine learning identify subtype- and symptom-associated signatures in systemic mastocytosis. 67th ASH Annual Meeting and Exposition, 2025. e-Pub 2025.
      8. Muftuoglu M, Singh S, Bedoy AD, Li L, Nath D, Ostermann LB, Veletic I, Pacheco CD, Mak PY, Ayoub E, Basyal M, Kim T, Luther S, Rohde CB, Andreeff M. Gene-modified iPS-derived MSC restore a ‘Hot’ immune microenvironment in high-grade serous ovarian cancer. AACR Special Conference in Cancer Research: Advances in Ovarian Cancer Research 85(18_Supplement):PR001, 2025. e-Pub 2025.
      9. Bose P, Pemmaraju N, Masarova L, Veletic I, Abbas H, Kornblau S, Maiti A, Jain N, Manshouri T, Wang X, Pinsoy M, Pierce S, Zhou L, Dobbins M, Kantarjian H, Estrov Z, Verstovsek S. Final results of a pilot study of elotuzumab in patients with myelofibrosis. 30th EHA Congress, 2025. e-Pub 2025.
      10. Singh S, Bedoy AD, Muftuoglu M, Nath D, Li L, Ostermann LB, Veletic I, Pacheco CD, Mak PY, Ayoub E, Basyal M, Kim T, Luther S, Rohde CB, Andreeff M. Engineering iPSC-derived mesenchymal stem cells (i MSCs) to secrete IL-7/IL-15 for modulation of the tumor microenvironment in a" cold" ovarian tumor model. 2025 ASCO Annual Meeting 43(16_suppl):2538, 2025. e-Pub 2025.
      11. Singh S, Bedoy A, Nath D, Chang KH, Ostermann LB, Veletic I, Pacheco CD, Mak PY, Ayoub E, Muftuoglu M, Basyal M, Kim T, Hinkel RD, Garland KM, Angel M, Luther S, Rohde CB, Andreeff M. iPS-derived MSC secreting IL7 and IL15 exert immune mediated anti-tumor activities. AACR Annual Meeting 2025 85(8_Supplement_1):3473, 2025. e-Pub 2025.
      12. Veletic I, Manshouri T, Yin CC, Pacheco CD, Ly CP, Dasdemir E, Cohen EN, Masarova L, Pemmaraju N, Bose P, Kantarjian HM, Estrov Z, Reville PK, Dunbar A, Abbas H. Temporal Dynamics of Bone Marrow Fibrocytes in the Progression of Primary Myelofibrosis. 66th ASH Annual Meeting and Exposition 144(Suppl 1):1760, 2024. e-Pub 2024.
      13. Ly CP, Veletic I, Pacheco CD, Dasdemir E, Jelloul FZ, Ferri-Borgogno S, Basi A, Gomez JA, Root JL, Reville PK, Quesada AE, Bueso-Ramos CE, Garcia MB, Burks JK, Abbas HA. Multimodal Spatial Profiling in Acute Myeloid Leukemia. 66th ASH Annual Meeting and Exposition 144(Suppl 1):2681, 2024. e-Pub 2024.
      14. Abbas HA, Nguyen A, Wang B, Chen M, Yang G, Lampson B, Erlich RL, Veletic I. Blood-Based Proteomics for Deeper Insights into Indolent Systemic Mastocytosis: The Pioneer Trial Experience. 66th ASH Annual Meeting and Exposition 144(Suppl 1):6569, 2024. e-Pub 2024.
      15. Dasdemir E, Veletic I, Ly CP, Quesada AE, Jelloul FZ, Borges P, Basu S, Jindal S, Wang Z, Lazar AJ, Wani KM, Antunes DA, Reville PK, Gunaratne P, Tower RJ, Sharma P, Abbas HA. Multimodal Spatial Transcriptomic Profiling Elucidates Niche-Specific Dynamics in Medullary and Extramedullary Acute Myeloid Leukemia. 66th ASH Annual Meeting and Exposition 144(Suppl 1):1059, 2024. e-Pub 2024.
      16. Wang B, Reville PK, Jelloul FZ, Desai PN, Borges P, Ly C, Veletic I, Dasdemir E, Burks JK, Tang G, Guo S, Vaugh N, Baran N, Deng Q, Matthews J, Gunaratne P, Antunes DA, Ekmekcioglu S, Sasaki K, Garcia MB, Cuglievan B, Hao D, Daver N, Green MR, Konopleva MY, Futreal A, Post SM, Abbas HA. IFNγ Signaling in Acute Myeloid Leukemia Mediates Immunomodulation and Reveals Therapeutic Strategies. 65th ASH Annual Meeting and Exposition 142(Suppl 1):2796, 2023. e-Pub 2023.
      17. Veletic I, Harris DM, Rozovski U, Li P, Liu Z, Manshouri T, Bertilaccio MTS, Calin GA, Drula RC, Takahashi K, Furudate K, Muftuoglu M, Hossain A, Ferrajoli A, Burger JA, Jain N, Wierda WG, Verstovsek S, Keating MJ, Estrov Z. CLL Cell-Derived Exosomes Impair Immune Function and Normal Hematopoiesis in CLL. 65th ASH Annual Meeting and Exposition 142(Suppl 1):3264, 2023. e-Pub 2023.
      18. Veletic I, Manshouri T, Pacheco CD, Yin CC, Zhang Y, Li P, Cohen EN, Gomez JA, Burks JK, Verstovsek S, Estrov Z. Neoplastic Monocyte-Derived Fibrocytes Induce Bone Marrow Fibrosis in Patients with Primary Myelofibrosis. 65th ASH Annual Meeting and Exposition 142(Suppl 1):4516, 2023. e-Pub 2023.
      19. Bose P, Masarova L, Pemmaraju N, Dobbins M, Jain N, Abbas H, Kornblau S, Maiti A, Veletic I, Manshouri T, Bledsoe S, Richie MA, Hall-Moore N, Zhou L, Wang X, Kantarjian H, Estrov Z, Verstovsek S. A pilot study of the anti-SLAMF7 monoclonal antibody, elotuzumab, in patients with myelofibrosis. 28th EHA Congress 7(S3):e5738496, 2023. e-Pub 2023.
      20. Ferri-Borgogno S, Gomez JA, Veletic I, Burks JK, Mok SC. Depicting spatially-resolved immune landscapes in long-term ovarian cancer survivors by imaging mass cytometry. AACR Special Conference: Tumor Immunology and Immunotherapy 10(Suppl 12):B31, 2022. e-Pub 2022.
      21. Rozovski U, Harris D, Li P, Liu Z, Manshouri T, Veletic I, Jain P, Ferrajoli A, Burger J, Bose P, Thompson P, Jain N, Verstovsek S, Wierda W, Keating M, Estrov Z. STAT3 Induces the Expression of GLI1 in Chronic Lymphocytic Leukemia Cells. SOHO 2021 Annual Meeting 21(Suppl 1):S322-S323, 2021. e-Pub 2021.
      22. Veletic I, Manshouri T, Li P, Yin CC, Post S, Verstovsek S, Estrov Z. GLI1 Promotes the Pro-Fibrotic Function of Monocyte-Derived Fibrocytes in Myelofibrosis. SOHO 2021 Annual Meeting 21(Suppl 1):230, 2021. e-Pub 2021.
      23. Rozovski U, Harris DM, Li P, Liu Z, Manshouri T, Veletic I, Jain P, Ferrajoli A, Burger JA, Bose P, Thompson PA, Jain N, Verstovsek S, Wierda WG, Keating MJ, Estrov ZE. Constitutively Activated STAT3 Induces the Production of PTX3 That Contributes to the Induction of Bone Marrow Reticulin Fibrosis in Patient with CLL. 61st ASH Annual Meeting and Exposition 134(Suppl 1):3024, 2019. e-Pub 2019.
      24. Rozovski U, Harris DM, Li P, Liu Z, Manshouri T, Veletic I, Jain P, Ferrajoli A, Burger JA, Bose P, Thompson PA, Jain N, Verstovsek S, Wierda WG, Keating MJ, Estrov ZE. Constitutively Activated STAT3 Induces the Expression of Gli1 in Chronic Lymphocytic Leukemia Cells. 61st ASH Annual Meeting and Exposition 134(Suppl 1):3018, 2019. e-Pub 2019.
      25. Manshouri T, Veletic I, Zhang Y, Bove JE IV, Li P, Harris DM, Liu Z, Cohen EN, Verstovsek S, Estrov ZE. STAT3-Induced Gli1 Promotes the Differentiation and Maturation of Myelofibrosis Fibrocytes. 61st ASH Annual Meeting and Exposition 134(Suppl 1):2961, 2019. e-Pub 2019.
      26. Yuan B, Ly S, Veletic I, Maldonado K, Zhou X, deCrombrugghe B, Andreeff M, Battula VL. Acute myeloid leukemia cells induce new bone formation by expanding osteoprogenitor niche in the bone marrow. AACR Annual Meeting 2019 79(Suppl 13):2040, 2019. e-Pub 2019.
      27. Veletic I, Manshouri T, Nogueras González GM, Prijic S, Bove JE IV, Zhang Y, Verstovsek S, Estrov ZE. PD-1-Mediated T Cell Exhaustion Is Prevalent Among Patients with MPN-Associated Myelofibrosis Independent of JAK1/2 Inhibition. 60th ASH Annual Meeting and Exposition 132(Suppl 1):5487, 2018. e-Pub 2018.
      28. Verstovsek S, Hasserjian RP, Pozdnyakova O, Veletic I, Mesa RA, Foltz L, Mascarenhas J, Ritchie EK, Palmer J, Silver RT, Kremyanskaya M, van den Blink B, Gupta R, Manshouri T, Yin CC, Estrov ZE, Gotlib JR. PRM-151 in Myelofibrosis: Efficacy and Safety in an Open Label Extension Study. 60th ASH Annual Meeting and Exposition 132(Suppl 1):686, 2018. e-Pub 2018.
      29. Manshouri T, Veletic I, Yin CC, Chen L, Bove JE IV, Zhang Y, Verstovsek S, Estrov ZE. Bone Marrow Fibrocytes Overexpress Gli1 Oncogenic Transcription Factor in Primary Myelofibrosis. 60th ASH Annual Meeting and Exposition 132(Suppl 1):1793, 2018. e-Pub 2018.
      30. Veletic I, Manshouri T, Newberry KJ, Bove JE, Zhang Y, Estrov Z, Verstovsek S. Increased Pentraxin-3 Correlates with the Activity of the Neoplastic Clone in Primary Myelofibrosis. 59th ASH Annual Meeting and Exposition 130(Suppl 1):5284, 2017. e-Pub 2017.
      31. Rozovski U, Harris DM, Li P, Liu Z, Manshouri T, Veletic I, Bueso-Ramos C, Jain P, Verstovsek S, Ferrajoli A, Burger JA, Bose P, Thompson PA, Jain N, Wierda WG, Keating MJ, Estrov Z. CLL Cell-Derived Exosomes Promote Bone Marrow Fibrosis and Inhibit Normal Hematopoietic Colony Proliferation. 59th ASH Annual Meeting and Exposition 130(Suppl 1):1728, 2017. e-Pub 2017.
      32. Veletic I, Manshouri T, Yin CC, Newberry KJ, Verstovsek S, Estrov Z. Neoplastic Monocyte-Derived Osteoclasts Are Highly Proliferative, but Sub-Functional in MPN-Associated Myelofibrosis. 59th ASH Annual Meeting and Exposition 130(Suppl 1):1664, 2017. e-Pub 2017.
      33. Veletic I, Manshouri T, Prijic S, Yin CC, Bove JE IV, Zhang Y, Verstovsek S, Estrov Z. Multiplex Quantitative Imaging Analysis of Bone-Remodeling Cells in Patients with Myelofibrosis. 58th ASH Annual Meeting and Exposition 128(22):4280, 2016. e-Pub 2016.
      34. Prijic S, Manshouri T, Veletic I, Newberry KJ, Zhang Y, Bove JE IV, Estrov Z, Verstovsek S. Loss of Normal T-Cell Subset Distribution in Myelofibrosis Is Recovered By the Immunomodulatory Effects of JAK1/2 Inhibition. 58th ASH Annual Meeting and Exposition 128(22):3138, 2016. e-Pub 2016.
      35. Prijic S, Manshouri T, Zhang Y, Veletic I, Zhang X, Bove IV JE, Estrov Z, Verstovsek S. Ruxolitinib Treatment Induces a Transition of Classical to Non-Classical Monocytes in Patients with Myelofibrosis. 57th ASH Annual Meeting and Exposition 126(23):2838, 2015. e-Pub 2015.
      36. Andreeff M, Singh S, Bedoy A, Muftuoglu M, Li L, Anand V, Nath D, Ostermann LB, Veletic I, Pacheco CD, Basya M, Kim T, Garland KM, Angel M, Luther S, Pierce R, Rohde CB. Engineered IL7/IL15 Secreting iPSC-Derived Mesenchymal Stromal Cells Convert the Immunosuppressive into Immune-Activated Tumor Microenvironments (TME) and Potentiate Antitumor Immunity. AACR Annual Meeting 2026.
      37. Kuo YA, Dasdemir E, Rebboah E, Veletic I, Wang B, Maiti A, Swaminathan M, Konopleva M, Jelloul FZ, Abbas HA. Optimization of a Xenium-based spatial transcriptomics workflow for bone marrows in hematologic malignancies. 2026 Single-Cell Cancer Biology GRC.
      38. Rebboah E, Kuo YA, Nguyen AH, Hachem M, Veletic I, Xiao W, Manshouri T, Pemmaraju N, Masarova L, Bose P, Marvin-Peek J, Abbas HA. Spatial transcriptomic dissection of a rare mast cell-driven bone marrow disease. 2026 Single-Cell Cancer Biology GRC.
      39. Rebboah E, Xiao W, Nguyen AH, Hachem M, Campoverde L, Veletic I, Manshouri T, Pemmaraju N, Masarova L, Bose P, Marvin-Peek J, Abbas HA. Integrative proteomics and machine learning identify subtype- and symptom-associated signatures in systemic mastocytosis. AIM 2026 Physician and Investigator Conference.
      40. Marvin-Peek J, Nguyen AH, Campoverde L, Rebboah E, Xiao W, Hachem M, Veletic I, Manshouri T, Braish J, El Hajjar G, Issa G, Pemmaraju N, Masarova L, Bose P, Abbas HA. Integrated Clinical and Molecular Registry with Longitudinal Biorepository in Systemic Mastocytosis: A Single-Institution Resource. AIM 2026 Physician and Investigator Conference.

      Letters to the Editor

      1. Veletic I, Manshouri T, Newberry KJ, Garnett J, Verstovsek S, Estrov Z. Pentraxin-3 plasma levels correlate with tumour burden and overall survival in patients with primary myelofibrosis. Br J Haematol 185: 382-386, 2019.

      Patents

      1. Estrov Z, Verstovsek S, Manshouri T, Veletic I. Production of megakaryocytes or platelets from monocytes, 2025. Patent Number: US 12,357,659.
      Read More
      Less

      Patient Reviews


      CV information above last modified July 22, 2026

      Request an Appointment

      Whether you are ready to make an appointment now or have questions for our expert team, we are standing by to help.
      Learn more

      Related Links

      • Care Centers and Clinics

      • Departments and Divisions

      • Labs

      Clinical Trials

      Our patients have access to clinical trials offering promising new treatments that cannot be found anywhere else.
      Learn more

      Help #EndCancer

      Give Now

      Your gift will help make a tremendous difference.
      Donate

      Donate Blood

      Our patients depend on blood and platelet donations.

      Make an appointment

      Shop UT MD Anderson

      Show your support for our mission through branded merchandise.

      View products
      Subscribe to our Cancerwise newsletter
      UT MD Anderson logoUT MD Anderson logo
      • Explore
      • Patients & Family
      • Prevention & Screening
      • Donors & Volunteers
      • For Physicians
      • Research
      • Education & Training
      • Clinical Trials
      • Languages
      • About
      • About UT MD Anderson
      • Careers
      • Blog
      • Newsroom
      • Editorial Standards
      • For Employees
      • Merchandise
      • Title IX Reporting (Sexual Misconduct)
      • Price Transparency
      • Finding Your Way
      • Our Doctors
      • Locations
      • Directions
      • Sitemap
      • DIGITAL ACCESSIBILITY
      • Accessibility Policy MD Anderson works with Level Access to ensure our website is accessible and functional for all users. Free assistive technology is provided for people with physical disabilities. To learn more or to download the assistive technology tool, visit https://www.levelaccess.com/MDAnderson
      • GET IN TOUCH
      • Call
        1-877-632-6789
      • Ask a question
      • Stay Connected
      • Cancerwise Podcast
      • More
      • Website Privacy Policy
      • Legal Statement & Policies
      • Reports to the State
      • Emergency Alert Information
      • State of Texas Links
      • Our Cancer Network
      • Vendors & Suppliers
      UT MD Anderson logo
      The mission of The University of Texas MD Anderson Cancer Center is to eliminate cancer in Texas, the nation, and the world through outstanding programs that integrate patient care, research and prevention, and through education for undergraduate and graduate students, trainees, professionals, employees and the public.

      © 2026 The University of Texas MD Anderson Cancer Center. All rights reserved.

      Top